volume in europe, a precursor?, page-2

Aaron,
I wonder if we will see PLE results at all (or if we do, they may be played down).
My sense is PLE is plan B for Clinuvel at this point.
It is all about orhpan indications. Why? See Cerezyme (Gauchers Disease) to understand why. It is based on:
- small number of patients (5,000 in the case of Gauchers)
- extremely high price for the drug (US$200,000 in case of Gauchers / Cerezye)
- high govt subsidies
Clinuvel can make substantial earnings from orphan indications, and can do so very quickly. It is the quickest route to market, and earnings.

PLE is a broad based market strategy. It is incompatible with an orphan approach - gestation period is longer, pricing strategy different (because low govt subsidies for broader application).

My sense is PLE is plan B at this stage. They'll pursue it further down the track once they have they are up and running with their orphan indications.